Oral News and Research

RSS

New drug can prevent life-threatening anaphylaxis, shows study

For someone with a food or drug allergy, the risk of life-threatening anaphylactic shock lurks around every corner. A new Northwestern Medicine study shows there might be a pill that can be taken proactively to prevent mild to life-threatening anaphylaxis, no matter the cause.

3 Jun 2020

Does interferon therapy work in COVID-19?

A new study published on the preprint site medRxiv in May 2020 reports on the efficacy of interferons in treating COVID-19. The research could help evaluate the place of such therapy in the management of this disease.

2 Jun 2020

People suffering from cluster headache often face a long delay in being diagnosed properly

New research led by Keele University has found that people suffering from cluster headache often face a long delay in being diagnosed correctly.

2 Jun 2020

Study maps novel coronavirus infection in cells of nasal cavity, airway and lungs

In a major scientific study published in the journal Cell, scientists at the UNC School of Medicine and the UNC Gillings School of Global Public Health have characterized the specific ways in which SARS-CoV-2 – the coronavirus that causes COVID-19 – infects the nasal cavity to a great degree – replicating specific cell types – and infects and replicates progressively less well in cells lower down the respiratory tract, including the lungs.

1 Jun 2020

Update on PALLAS triaI evaluating adjuvant palbociclib for early breast cancer

The Austrian Breast & Colorectal Cancer Study Group, Alliance Foundation Trials, the Breast International Group, PrECOG, LLC, the German Breast Group, and the NSABP Foundation today announced that the independent Data Monitoring Committee for the global Phase 3 early breast cancer PALbociclib CoLlaborative Adjuvant Study trial determined that the study is unlikely to show a statistically significant improvement in the primary endpoint of invasive disease-free survival following a preplanned interim analysis.

1 Jun 2020

Oral antidiabetics improve outcomes in diabetics with colorectal cancer

Bottom Line: Among patients with both colorectal cancer and diabetes in Korea, those who had a high adherence to their oral diabetes medication had a significantly reduced risk of overall mortality compared with those with lower adherence.

1 Jun 2020

Study compares cediranib plus olaparib and standard of care therapy for platinum-sensitive ovarian cancer

Results of the NRG Oncology phase III clinical trial NRG-GY004 indicated that the addition of the investigational agent cediranib to olaparib and standard platinum-based chemotherapy did not improve progression-free survival (PFS) outcomes for women with platinum-sensitive ovarian cancer; however, activity between the treatments was similar in patients.

30 May 2020

New review analyzes appropriateness of off-pathway cancer care

Clinical oncology pathways are an important tool, helping cancer care providers and their patients to zero in on the most appropriate care plan.

30 May 2020

Expert offers COVID-19 guidance for patients with COPD

Chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema, is a chronic lung disease that makes it hard to breathe. The disease affects millions of Americans and is the fourth leading cause of disease-related death in the U.S. People with COPD have a higher risk of more severe illness from COVID-19 due to their existing lung problems.

30 May 2020

Newer treatment approaches may reduce risk of therapy-related hematologic cancers

While breakthrough treatments have emerged for several cancers over the last two decades, driving striking improvements in survival and other clinical outcomes, too little is known about the risk of therapy-related hematologic cancers following targeted and immunotherapeutic approaches.

29 May 2020

Clinical trial shows anti-tumor responses in metastatic castration-resistant prostate cancer patients

The preliminary results of a Phase I clinical trial conducted by researchers at the Yale Cancer Center have shown that ARV-110, an androgen receptor PROTAC protein degrader, demonstrates clinical evidence of anti-tumor responses in patients with metastatic castration-resistant prostate cancer (mCRPC) who have failed prior therapy.

29 May 2020

C-DOCTOR receives $30-million grant from NIDCR for tissue and organ regeneration research

The initiative aims to propel USC forward as the epicenter of tissue and organ regeneration research.

29 May 2020

Monoclonal antibody therapy achieves modest reduction in recurrence for patients with HER2-positive DCIS

The addition of the monoclonal antibody therapy Trastuzumab to radiotherapy did not reach the protocol objective of a 36% reduction in the ipsilateral breast tumor recurrence rate for women with HER2-positive ductal carcinoma in situ (DCIS) on the NRG Oncology clinical trial NSABP B-43.

29 May 2020

Adoptive T-cell therapy targeting MAGE-A4 achieves responses in patients with multiple solid tumors

The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses in patients with multiple solid tumor types, including synovial sarcoma, head and neck cancer and lung cancer, according to results from a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

29 May 2020

Targeted therapy tepotinib shows durable response in NSCLC patients with METex14 skipping mutation

Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping mutation had a 46.5% objective response rate to the targeted therapy drug tepotinib, as shown in a study published today in the New England Journal of Medicine and presented at the 2020 American Society of Clinical Oncology Annual Meeting ASCO20 Virtual Meeting (Abstract 9556 - Poster 322) by researchers from The University of Texas MD Anderson Cancer Center.

29 May 2020

Targeted therapy pralsetinib shows high response rates in patients with RET fusion-positive cancers

The targeted therapy pralsetinib appears to have high response rates and durable activity in patients with a broad variety of tumors harboring RET gene fusions, according to results from the international Phase I/II ARROW trial, led by researchers at The University of Texas MD Anderson Cancer Center.

29 May 2020

Cancer drug nilotinib found to be safe and well-tolerated in Alzheimer's disease clinical trial

A Georgetown University Medical Center clinical trial investigating the cancer drug nilotinib in people with Alzheimer's disease finds that it is safe and well-tolerated, and researchers say the drug should be tested in a larger study to further determine its safety and efficacy as a potential disease-modifying strategy.

29 May 2020

New tool may predict best treatment for multiple myeloma

In 1844, multiple myeloma was first treated with a rhubarb pill and an infusion of orange peel. Since then, more than 15 drugs have earned FDA approval to treat multiple myeloma and with so many options, a major question has become what cocktail and sequence is best?

29 May 2020

Targeted therapy shows immense benefit for patients with early stage NSCLC

According to findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery significantly improves disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations.

29 May 2020

Combination therapy found to be effective against IDH1-mutated acute myeloid leukemia

A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective against a specific genetic subtype of acute myeloid leukemia (AML) in a Phase Ib/II trial led by researchers at The University of Texas MD Anderson Cancer Center.

28 May 2020

Oral News and Research

New drug can prevent life-threatening anaphylaxis, shows study

Does interferon therapy work in COVID-19?

People suffering from cluster headache often face a long delay in being diagnosed properly

Study maps novel coronavirus infection in cells of nasal cavity, airway and lungs

Update on PALLAS triaI evaluating adjuvant palbociclib for early breast cancer

Oral antidiabetics improve outcomes in diabetics with colorectal cancer

Study compares cediranib plus olaparib and standard of care therapy for platinum-sensitive ovarian cancer

New review analyzes appropriateness of off-pathway cancer care

Expert offers COVID-19 guidance for patients with COPD

Newer treatment approaches may reduce risk of therapy-related hematologic cancers

Clinical trial shows anti-tumor responses in metastatic castration-resistant prostate cancer patients

C-DOCTOR receives $30-million grant from NIDCR for tissue and organ regeneration research

Monoclonal antibody therapy achieves modest reduction in recurrence for patients with HER2-positive DCIS

Adoptive T-cell therapy targeting MAGE-A4 achieves responses in patients with multiple solid tumors

Targeted therapy tepotinib shows durable response in NSCLC patients with METex14 skipping mutation

Targeted therapy pralsetinib shows high response rates in patients with RET fusion-positive cancers

Cancer drug nilotinib found to be safe and well-tolerated in Alzheimer's disease clinical trial

New tool may predict best treatment for multiple myeloma

Targeted therapy shows immense benefit for patients with early stage NSCLC

Combination therapy found to be effective against IDH1-mutated acute myeloid leukemia

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News